Cancer Stem Cell News 9.06 February 19, 2020 | |
| |
TOP STORYInhibiting WNT and NOTCH in Renal Cancer Stem Cells and the Implications for Human Patients Scientists used cancer stem cells (CSCs) to establish non-adherent sphere cultures, 3D tumor organoids, and xenografts. Treatment with WNT and NOTCH inhibitors blocked the proliferation and self-renewal of CSCs in sphere cultures and organoids. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)FOXM1 Regulates Leukemia Stem Cell Quiescence and Survival in MLL-Rearranged AML Inhibition of FOXM1 markedly suppressed leukemogenic potential and induced apoptosis of primary leukemia stem cells from mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) patients in vitro and in vivo in xenograft mice. [Nat Commun] Full Article Monoamine oxidase A (MAOA) in stromal fibroblasts provided tumor cell growth advantages through paracrine IL-6/STAT3 signaling. Downstream of stromal MAOA, STAT3 promoted cell stemness and transcriptionally activated expression of cancer stem cell marker CD44 in prostate cancer cells. [Oncogene] Abstract CUL4B Contributes to Cancer Stemness by Repressing Tumor Suppressor miR34a in Colorectal Cancer Investigators aimed to identify the new regulators of colorectal cancer stem cells and found that Cullin 4B (CUL4B), which possessed oncogenic properties in multiple solid tumors, drove the development and metastasis of colon cancer by sustaining cancer stem-like features. [Oncogenesis] Full Article The authors examined dynamic responses in populations of a cancer stem cell phenotype in head and neck cancer cell lines following X-irradiation at therapeutic levels, and comparing between HPV statuses. [Sci Rep] Full Article Researchers investigated the impact of nandrolone on the metabolic phenotype in a HepG2 cell line. Nandrolone caused a significant increase of stemness-markers in both 2D and 3D cultures. [Sci Rep] Full Article A tumor sphere assay was performed to evaluate the self-renewal ability of hepatocellular carcinoma (HCC) cells. In addition, the molecular regulation between secretory clusterin and AKT/GSK-3β/β-catenin axis in HCC cells were discovered by western blotting, quantitative real-time PCR, and immunofluorescence. [J Transl Med] Full Article Targeting Glioma-Initiating Cells via the Tyrosine Metabolic Pathway Comprehensive metabolic analyses were performed on 20 high-grade glioma tissues and 30 glioma-initiating cell sphere culture models. Scientists suggested that tyrosine metabolism could serve as a possible therapeutic target in glioblastoma, particularly in the tumor core. [J Neurosurg] Abstract Researchers found that MYH9 was an effective promoter of tumor stemness that facilitated hepatocellular carcinoma pathogenesis. Targeting MYH9 blocked HBX protein-induced GSK3β ubiquitination to activate the β-catenin destruction complex and suppressed cancer stemness and EMT. [Signal Transduct Target Ther] Full Article Subscribe to one of our other 19 science newsletters such as Neural Cell News & Hematopoiesis News. | |
| |
REVIEWSNovel Ablation Methods for Treatment of Gliomas The authors review the most common primary brain tumors, as a need exists for new approaches to tumor therapy that can circumvent the blood brain barrier, target highly resistant tumors and cancer stem-like cells as well create an anti-cancer immunomodulatory environment. [J Neurosci Methods] Abstract Visit our reviews page to see a complete list of reviews in the cancer stem cell research field. | |
| |
INDUSTRY NEWSBristol-Myers Squibb Company announced that the FDA has accepted for Priority Review its BLA for liso-cel, the company’s autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T cells for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after at least two prior therapies. [Bristol-Myers Squibb Company] Press Release Merck, Inc. announced that the FDA has issued a Complete Response Letter regarding Merck’s sBLAs seeking to update the dosing frequency for KEYTRUDA®, Merck’s anti-PD-1 therapy, to include a 400 mg dose infused over 30 minutes every-six-weeks option in multiple indications. [Merck, Inc.] Press Release | |
| |
POLICY NEWSThe Next Chapter for African Genomics Nigeria is poised to become a hub for genetics research, but a few stubborn challenges block the way. [Nature News] Editorial ‘The Disruption Is Enormous.’ Coronavirus Epidemic Snarls Science Worldwide Normal daily life has come to a virtual standstill in large parts of China as a result of the epidemic of COVID-19—and so has science. Universities across the country remain closed; access to labs is restricted, projects have been mothballed, field work interrupted, and travel severely curtailed. [ScienceInsider] Editorial
| |
EVENTSNEW Keystone Symposia: Hematopoiesis Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Associate – Glioma Stem Cell Biology (Cornell University) Postdoctoral Fellow – Translational Brain Tumor Research (Northwestern University) Postdoctoral Studentship and PhD Position – Cancer Cell Plasticity (Giessen University) Postdoctoral Position – Stemness in Epigenetic Regulation (University of Freiburg) Postdoctoral Fellow – Research in Cancer Progression (The Wistar Institute) Postdoctoral Position – Bioinformatics and Leukemia Stem Cells (The Centre for Genomic Regulation) Postdoctoral Fellow – Clonal Evolution of Cancer (Moffitt Cancer Center & Research Institute) Postdoctoral Position – Glioma and Neurodevelopment (Mount Sinai) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|